ACTRN12615001100583已完成1 期
A single dose, randomized, open label, pharmacokinetic and pharmacodynamic study of inhaled insulin in a 3 way crossover comparison against the innovators Humalog KwikPen for injection and the AFREZZA Inhalation Powder Cartridge conducted under fasting conditions in healthy male and female volunteers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •Healthy male and non-pregnant females
- •Aged between 18 and 55
- •Non-smoker
- •BMI between 18 and 30 inclusive
- •Normal, healthy individuals as determined by medical history, physical examination, ECG, blood pressure, spirometry, oximetry, chest x-ray and laboratory tests
- •Able to provide written informed consent
排除标准
- •Any history of recent recurrent attacks of bronchitis, COPD, emphysema, bronchitis, asthma, migraine headaches
- •Concomitant drug therapy of any kind
- •Sensitivity to insulin or any other similar class of medicines, or the excipients of insulin
- •History of any conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug
- •Females who are pregnant and/or are breastfeeding
- •Smoker (anyone who has smoked in the last 6 months)
- •History of alcohol or drug abuse or dependency
- •Participation in a drug study within 60 days of the start of the study or donated blood in the 60 days preceding the study.
- •Volunteers for whom the Clinical Investigator believes, for any reason, that participation would not be an acceptable risk
研究者
相似试验
已完成
1 期
Comparative assessment of the absorption of a generic formulation of 5 mg bis [(E)-7-[4-(4-fluorophenyl)- 6-isopropyl-2- [methyl(methylsulfonyl) amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt orally disintegrated tablet (ODT) against the innovator 40 mg bis [(E)-7-[4-(4-fluorophenyl)- 6-isopropyl-2- [methyl(methylsulfonyl) amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt oral tablet conducted under fasting conditions in healthy volunteers.bis [(E)-7-[4-(4-fluorophenyl)- 6-isopropyl-2- [methyl(methylsulfonyl) amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt is indicated in patients with no hyperchloesterolaemia as an adjunct to diet when the response to diet and exercise is inadequate.Cardiovascular - Other cardiovascular diseasesACTRN12621001409864Zenith Technology Corporation Limited16
已完成
1 期
Comparative assessment of the absorption of a generic formulation of 5/2.5 mg s 4,5a-epoxy14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride/naloxone tablet against the innovator 5/2.5 mg s 4,5a-epoxy14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride/naloxone tablet conducted under fasting conditions in healthy volunteers.ACTRN12620000327987Zenith Technology Corporation Limited26
已完成
1 期
Comparative assessment of the absorption of a test formulation of 1 x 30 mg isotretinoin capsule against the innovator 1 x 30 mg isotretinoin capsule conducted under fed conditions in healthy male volunteers.Isotretinoin is a medicine that is used to treat severe forms of acne.Skin - Dermatological conditionsACTRN12618000935235Zenith Technology Corporation Limited32
已完成
1 期
Comparative assessment of the absorption of a test formulation of 1 x 40 mg isotretinoin capsule against the innovator 1 x 40 mg isotretinoin capsule conducted under fed conditions in healthy male volunteers.Isotretinoin is a medicine that is used to treat severe forms of acne.Skin - Dermatological conditionsACTRN12619000154101Zenith Technology Corp Ltd42
已完成
1 期
Comparative assessment of the absorption of a test formulation of 1 x 30 mg isotretinoin capsule against the innovator 1 x 30 mg isotretinoin capsules conducted under fasting conditions in healthy male volunteers.Isotretinoin is a medicine that is used to treat severe forms of acne.Skin - Dermatological conditionsACTRN12617001407381Zenith Technology Corp Ltd46